Biology Reference
In-Depth Information
McSharry JJ, Costantino R, Robbiano E, Echols R, Stevens R, Lehman JM. 1990. Detection and
quantitation of human immunode®ciency virus-infected peripheral blood mononuclear cells by
¯ow cytometry. J Clin Microbiol 28: 724±733.
Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan M, Poon S, Fung MS,
Traincard F, Pinkus M, Robey G, Robinson JE, Ho DD, Sodroski J. 1993. Probing the struc-
ture of the V2 domain of human immunode®ciency virus type 1 surface glycoprotein gp120 with
a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J
Virol 67: 6136±6151.
Oberlin E, Amaran A, Bachelerie F, Bessia C, Virelizier J, Arenzanan-Seisdedos F, Schwartz O,
Heard J, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B. 1996. The CXC
chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted
HIV-1. Nature 382: 833±836.
Ohlsson-Wilhelm BM, Cory JM, Kessler HA, Eyster ME, Rapp F, Landay A. 1990. Circulating
human immunode®ciency virus (HIV) p24 antigen-positive lymphocytes: a ¯ow cytometric
measure of HIV infection. J Infect Dis 162: 1018±1024.
Perez VL, Rowe T, Justement JS, Butera ST, June C, Folks T. 1991. An HIV-1-infected T cell clone
defective in IL-2 production and Ca2
mobilization after CD3 stimulation. J Immunol 147:
3145±3148.
Pincus SH, Wehrly K, Chesebro B. 1989. Treatment of HIV tissue culture infection with mono-
clonal antibody-ricin A chain conjugates. J Immunol 142: 3070±3075.
Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker LJ. 1999. HIV-1-
speci®c CD4
T cells are detectable in most individuals with active HIV-1 infection, but decline
with prolonged viral suppression. Nat Med 5: 518±525.
Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. 1991. An IgG human
monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neu-
tralizes infection. J Immunol 146: 4325±4332.
Saha K, Bentsman G, Chess L, Volsky DJ. 1998. Endogenous production of beta-chemokines by
CD4
, but not CD8
, T-cell clones correlates with the clinical state of human immunode®ciency
virus type 1 (HIV-1)infected individuals and may be responsible for blocking infection with non-
syncytium-inducing HIV-1 in vitro. J Virol 72: 876±881.
Sampson M, Libert R, Doranz BJ, Rucker J, Liesnard C, Farber C, Saragosti S, Lapoumeroulie C,
Cognaux J, Forceille C, Myldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T,
Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. 1996. Resistance
to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine re-
ceptor gene. Nature 382: 722±725.
Schols D, Proost P, Damme JV, Clercq ED. 1997. RANTES and MCP-3 inhibit the replication of
T-cell-tropic human immunode®ciency virus type 1 strains (SF-2, MN, and HE). J Virol 71:
7300±7304.
Schubert U, Anton LC, Backik I, Cox JH, Bour S, Bennink JR, Orlowski M, Strebel K, Yewdell
JW. 1998. CD4 glycoprotein degradation induced by human immunode®ciency virus type 1 Vpu
protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol 72:
2280±2288.
Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. 1996. Endocytosis of major histo-
compatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2: 338±
342.
Secchiero P, Zella D, Capitani S, Gallo RC, Zauli G. 1999. Extracellular HIV-1 Tat protein
up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4
T cells.
J Immunol 162: 2427±2431.
Sharma V, Xu M, Ritter LM, Wilkie NM. 1996. HIV-1 Tat induces the expression of a new hema-
topoietic cell-speci®c transcription factor and downregulates MIP-1 alpha gene expression in
activated T-cells. Biochem Biophys Res Commun 223: 526±533.
